Search 

Focused in genitourinary（GU）/women health field with 2 global assets for bladder cancer and pre-cervical cancer treatment in phase 3 stages，looking for in/out-licensing partnership in GU/women health area

Avanc Pharmaceutical Co., Ltd (Avanc Pharma or the Company), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, focuses on innovative drug R&D, production and distribution and has a long-term commitment to nervous system, oncology, perioperative drugs and pediatric drugs.

Celumigen Pharmaceuticals is a California- headquartered seed stage specialty pharmaceutical company in dermatology focused on developing the first FDA-approved topical prescription immunotherapeutic drug for Cutaneous viral warts; a widespread global disease affecting greater than 500MM people in China, and 78% of the world's population. The global markets have seen no approved prescription therapies for HPV, Common warts and no therapies that eradicate this disease on the market or in the pipeline-- we plan to capture and grow this lucrative market. Our therapeutic is a likely 505 (b) 2 FDA designated drug. Our leadership, development and clinical team is a group of world class leaders with deep industry knowledge and unparalleled domain expertise. We have raised a seed round led by industry- leading investors which funded a Proof of Concept study with very positive confirmatory results and data to support our Phases I and Phase II. We are now seeking strategic partnership with a company seeking to support drug development to enhance existing dermatology drug asset portfolios or fund our program through venture capital / partnership.

Credevo is a global clinical research and development company that acts as an extended arm of Biopharma companies to facilitate clinical development and product registrations worldwide.

A clinical-stage pharma company with a P2B asset targeted
for multiple psychiatric disorders with unmetmedical needs.
The parent company, Generys Therapeutics Corp.
headquartered in Rep. of Korea is a controlled foreign
company (US IRS code).

We are a pharmaceutical startup in Memphis, Tennessee. Our focus is on pediatric drug delivery designs as we transform FDA approved therapeutic compounds into pediatric friendly drug delivery systems. We have designed several Epinephrine prodrugs to eliminate the need to use Epipen injections. We seek seed funding for organic synthesis, formulation development and CMC drug development.

As an investment and management platform established by UK-listed company Cathay International Holdings Limited, Lansen has built up pharmaceutical segment, health segemtn and cosmetic segment. Lansen has been listed in Stock Exchange of Hong Kong Limited (SEHK) on May 7, 2010. Lansen's top products are in rheumatology and dermatology area, and Lansen has established an extensive distribution network, with more than 300 frontline sales staff and more than 1500 distributors. By licensing in promising products at commercial stage and clinical stage, or other cooperation patterns, Lansen plans to expand to more diseases medication market, including rheumaotlogy, dermatology, orthopedics and nephrology.

China top 3 pharma company in both commercialization and manufacturing sales. Dual listed on HK and Shanghai stock exchange market .